局限性前列腺癌主动监测与观察等待的决策模型比较
本研究建立马尔可夫模型,比较美国50岁起确诊局限性前列腺癌并选择保守管理的男性中,观察等待与不同主动监测策略的预期寿命和生活质量。所有主动监测策略均较观察等待延长寿命,但主动监测的前列腺癌死亡和转移风险更低;在诊断年龄>65岁或治疗并发症长期存在时,主动监测的质量调整生命年不再优于观察等待。
要点
- 所有主动监测策略均较观察等待延长寿命,前列腺癌死亡风险5.42% vs 8.72%。
- 主动监测转移风险6.40% vs 观察等待10.30%,但30-41%在10年内接受根治性治疗。
- 诊断年龄>65岁或治疗并发症长期存在时,主动监测质量调整生命年不再优于观察等待。
核心结论
- 主动监测较观察等待延长寿命,尤其对高风险特征男性,但部分被后续治疗导致的生活质量下降所抵消。
研究设计与样本
- 马尔可夫模型,模拟美国50岁起确诊局限性前列腺癌并选择观察等待或主动监测(不同检测方案)的男性,参数来自文献。
主要发现
- 主动监测的前列腺癌死亡风险5.42%、转移风险6.40%,观察等待分别为8.72%和10.30%。
- 所有主动监测策略均较观察等待延长寿命。
- 除诊断年龄>65岁或治疗相关并发症长期存在外,主动监测较观察等待获得更多质量调整生命年。
- 根据主动监测方案不同,30-41%在10年内接受根治性治疗。
- 将监测活检间隔从1年延长至5年,寿命略有缩短,质量调整生命年差值为0.26。
关键数值与推荐
- 主动监测:前列腺癌死亡风险5.42%,转移风险6.40%;观察等待:分别为8.72%和10.30%。
- 主动监测10年内根治性治疗比例30-41%(取决于方案)。
- 活检间隔从1年延长至5年,质量调整生命年差值为0.26。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: An increasing proportion of prostate cancer is being managed conservatively. However, there are no randomized trials or consensus regarding the optimal follow-up strategy. OBJECTIVE: To compare life expectancy and quality of life between watchful waiting (WW) versus different strategies of active surveillance (AS). DESIGN, SETTING, AND PARTICIPANTS: A Markov model was created for US men starting at age 50, diagnosed with localized prostate cancer who chose conservative management by WW or AS using different testing protocols (prostate-specific antigen every 3-6 mo, biopsy every 1-5 yr, or magnetic resonance imaging based). Transition probabilities and utilities were obtained from the literature. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Primary outcomes were life years and quality-adjusted life years (QALYs). Secondary outcomes include radical treatment, metastasis, and prostate cancer death. RESULTS AND LIMITATIONS: All AS strategies yielded more life years compared with WW. Lifetime risks of prostate cancer death and metastasis were, respectively, 5.42% and 6.40% with AS versus 8.72% and 10.30% with WW. AS yielded more QALYs than WW except in cohorts age >65 yr at diagnosis, or when treatment-related complications were long term. The preferred follow-up strategy was also sensitive to whether people value short-term over long-term benefits (time preference). Depending on the AS protocol, 30-41% underwent radical treatment within 10 yr. Extending the surveillance biopsy interval from 1 to 5 yr reduced life years slightly, with a 0.26 difference in QALYs. CONCLUSIONS: AS extends life more than WW, particularly for men with higher-risk features, but this is partly offset by the decrement in quality of life since many men eventually receive treatment. PATIENT SUMMARY: More intensive active surveillance protocols extend life more than watchful waiting, but this is partly offset by decrements in quality of life from subsequent treatment.
引用
- Loeb S, Zhou Q, Siebert U, et al. Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions. Eur Urol. 2017. PMID: 28844371. doi:10.1016/j.eururo.2017.07.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。